TROY, Mich., July 24, 2020 /PRNewswire-PRWeb/ -- Inspired by the ceremonies namesake, Florence Nightingale, committee members carried on the 32 year tradition by providing an innovative virtual mixer and live stream ceremony that applauds the dedication and commitment of outstanding nursing professionals who actively shape the future healthcare. This year, AmeriCare Medical, Inc. partnered with Oakland University as a scholarship sponsor for Post Acute Care and Specialty Nursing with Paula Lavesque from Beaumont Health Systems taking home the prestigious nursing award.
"The award night event proved to be like no other, along with the virtual setting, it is the 200th Anniversary of Florence Nightingale's birth year and the World Health Organization designated 2020 as the Year of the Nurse," stated Greg Jamian, CEO of AmeriCare Medical, Inc., and board member of the Oakland University School of Nursing. "Now more than ever, we are proud and honored to once again continue our partnership with Oakland University to recognize nursing leaders who integrate life-long learning, skills and values into their professional practice within our community."
AmeriCare's company, AmeriStaff Nursing Services has been an exemplary employer of the nursing fields, and currently employs over 300 nurses to businesses, hospitals, governments and assisted care facilities throughout Michigan. Two thirds of AmeriStaff's Nursing Management Team are alumni of the Oakland University's School of Nursing.
There were eleven Nightingale award winners and another eleven runner-ups that received scholarships or recognition for exceptional service. For over three decades, this has been a night to acknowledge and strengthen the entire southeastern Michigan nursing community.
Since 1980, AmeriCare Medical, Inc. has provided integrated health care services to hospitals, assisted care facilities and private homes throughout Michigan. AmeriCare Medical, Inc. is the parent company of AmeriStaff Nursing Services, Sun Medical Equipment and Rx iV Pharmacy, making it a one stop shop for patients and all of their home care needs. For more information visit: https://www.americaremedical.com# # # #
SOURCE AmeriCare MedicalInc.
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product LUMEVOQ® to the European Medicines Agency (EMA), seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by mutation in the ND4 mitochondrial gene.
"This first regulatory submission for GenSight is a major milestone in our progression from a pure research organization to one with commercial capabilities. It validates a technology platform that has the potential to address the high unmet medical needs of patients suffering from a range of rare diseases. I would like to thank all GenSight employees and partners whose motivation, focus and effort made this submission possible,” said Bernard Gilly, Co-founder and Chief Executive Officer of GenSight Biologics.
LHON is a rare, mitochondrial genetic disease, mainly affecting young males. The ND4 mutation results in the worst visual outcomes, with most patients becoming legally blind. There continues to be a high unmet medical need for the 800-1200 new LHON patients in Europe and the U.S. each year, particularly those who are struck blind in their prime working years.
Lenadogene nolparvovec (tradename: LUMEVOQ®) is a recombinant adeno-associated viral vector, serotype 2 (rAAV2/2), containing a cDNA encoding the human wild-type mitochondrial NADH dehydrogenase 4 protein (ND4), which has been specifically developed for the treatment of LHON associated with mutation in the ND4 gene. It received orphan drug designation status for the treatment of LHON from the EMA in 2011 and from the U.S. Food and Drug Administration (FDA) in 2013.
GenSight submitted the MAA based on the benefit-risk balance established by results from a Phase-I/IIa study (CLIN-01), two pivotal Phase-III efficacy studies (CLIN-03A: RESCUE, and CLIN-03B: REVERSE) and the long-term follow up study of RESCUE and REVERSE (CLIN 06 - readout at Year 3 post injection). To demonstrate the efficacy of LUMEVOQ® in the context of a contralateral effect, the Company used a statistics-based indirect comparison methodology to assess the visual outcomes in LUMEVOQ®-treated patients (from LUMEVOQ® efficacy studies) against those in untreated patients from Natural History studies and GenSight’s REALITY Natural History Registry.
GenSight expects to submit the Biologics License Application (BLA) for LUMEVOQ® to the FDA in H2 2021. First-in-human data from GenSight’s second clinical stage program, GS030, are expected to be available in H2 2021.
About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to the eye by intravitreal injection to offer patients a sustainable functional visual recovery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005857/en/
LISLE, Ill., April 28, 2021 /PRNewswire/ -- Today, SunCoke Energy, Inc. (NYSE: SXC) announced that its Board of Directors declared a cash dividend of $0.06 per share of the Company's common stock to be paid June 1, 2021 to stockholders of record at the close of business on May 19, 2021. ABOUT SUNCOKE ENERGY, INC.SunCoke Energy, Inc. (NYSE: SXC) supplies high-quality coke used in the blast furnace production of steel, under long-term, take-or-pay contracts that pass through commodity and certain operating costs to customers. We utilize an innovative heat-recovery technology that captures excess heat for steam or electrical power generation. Our cokemaking facilities are located in Illinois, Indiana, Ohio, Virginia and Brazil. We have more than 60 years of cokemaking experience serving the integrated steel industry. In addition, we provide export and domestic material handling services to coke, coal, steel, power and other bulk and liquids customers. Our logistics terminals have the collective capacity to mix and transload more than 40 million tons of material each year and are strategically located to reach Gulf Coast, East Coast, Great Lakes and international ports. To learn more about SunCoke Energy, Inc., visit our website at www.suncoke.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/suncoke-energy-inc-declares-cash-dividend-301278446.htmlSOURCE SunCoke Energy, Inc.